Transport Pharmaceuticals’ Device/Drug Combo For Herpes To Launch In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Pivotal, Phase III U.S. trial for iontophoresis drug delivery device is expected to begin in late 2005. The combo product’s drug ingredient is acyclovir, and FDA’s drug center will take the lead on pre-market review, Transport says.
You may also be interested in...
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.